Cash Position: Ended the quarter with $178.36 million in cash and cash equivalents, down from $193.51 million at the end of the previous quarter.

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...

GSK said in the first quarter of 2024, the sales of Specialty Medicines increased, driven by strong HIV and Oncology ...

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and ...

GSK plc GSK reported core earnings of $1.09 per American depositary share (“ADS”) in first- quarter 2024, beating the Zacks ...

Sales of COPD inhalers Trelegy Ellipta, Breo Ellipta and Anoro Ellipta are likely to have contributed to first-quarter 2024 sales. Our model suggests Trelegy Ellipta, Breo Ellipta and Anoro Ellipt ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR ®/BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva's other innovative healthcare assets include infectious disease and critical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...